Skip to main content
. 2013 Feb 1;48(2):143–152. doi: 10.1310/hpj4802-143

Table 4.

Adverse reactions reported in ≥ 2% of linaclotide-treated (145 mcg) patients and at an incidence greater than in placebo group patients in the 2 phase 3, placebo-controlled trials (1 and 2) in irritable bowel syndrome with constipation1

Adverse reactions Linaclotide 145 mcg (n = 430) Placebo (n = 423)
Diarrhea 16% 5%

Abdominal pain 7% 6%

Flatulence 6% 5%

Upper respiratory tract infection 5% 4%

Sinusitis 3% 2%

Abdominal distension 3% 2%